Ulcerative Colitis

For safety, 24.1% of the entire study population experienced adverse events, with 18 participants developing tuberculosis.

The investigators found that depression increased the odds of systemic steroid administrations, the use of 2 or more molecular targeted drugs, and surgery in patients with ulcerative colitis.

New pooled phase 3 data presented at ACAAI 2022 supports the FDA's approval of dupilumab for eosinophilic esophagitis.

More than 70% of patients treated with RBX2660 were recurrence free at the 8 week mark.

The approval of risankizumab represents the first ever IL-23 approved by the FDA for IBD.

Patients with obesity have higher costs and longer hospital stays for IBD.

Up to 2% of patients with IBD also have EoE.

Guselkumab bested placebo in clinical results of patients with ulcerative colitis.

In a late-breaking abstract, the investigators compared antibody levels at month 6 compared to month 1.

A greater proportion of the upadacitinib 15 mg and upadacitinib 30 mg group achieved clinical remission based on the Crohn’s Disease Activity Index

Extended induction treatment with upadacitinib 45 mg led to achievement of clinical response in a clinically meaningful proportion of patients with ulcerative colitis who do not respond to 8 weeks of induction therapy.

Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.

Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.

The approval of risankizumab represents the first IL-23 approved for IBD.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

The rate of serious infections was 5.9 events per 100 person-years in the placebo group, compared to 5.0 events in the upadacitinib 15 mg cohort and 3.2 upadacitinib 30 mg group.

The study results are consistent with previous meta-analyses that show the efficacy of FMT in patients with IBD compared to placebo.

Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.

At 14 week, 33% of patients in the 210 mg induction etrolizumab group were in clinical remission, compared to 29% of the placebo induction group.

Several factors that impaired healing included former smoking and seton insertion.

The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.

In total, 64.9% of patients who achieved clinical response with ustekinumab during induction were in symptomatic remission after 44 weeks.

Recent qualitative studies found social isolation in patients with IBD is 1 of the main obstacles to leading a normal life.

The FDA approved risankizumab for patients with Crohn's disease in June.

The genus most consistently associated with Crohn’s disease was Fusobacterium, but disease-associated genera were mostly inconsistent between studies.